GNF2133是一种高效、选择性的DYRK1A抑制剂,对DYRK1A和GSK3β的IC50值分别为0.0062 µM和>50 µM。GNF2133 能够促进大鼠和人类原代β细胞的增殖,显著提高葡萄糖处理能力和胰岛素分泌,具有研究1型糖尿病的潜力。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | GNF2133 is a potent, selective, and orally bioavailable DYRK1A inhibitor with an IC50 of 0.0062 μM for DYRK1A and over 50 μM for GSK3β. It displays strong proliferative effectiveness on rat and human primary β-cells, significantly enhances glucose disposal, and boosts insulin secretion. GNF2133 holds potential for research into type 1 diabetes[1]. |
体内研究 | GNF2133, administered orally at a dose of 30 mg/kg, demonstrates favorable oral absorption with a bioavailability of 22.3%[1]. NF2133, given orally at 30 mg/kg daily for five days, has shown the capacity to promote β-cell proliferation in vivo[1]. NF2133 at doses of 3, 10, and 30 mg/kg markedly enhances glucose disposal and boosts insulin secretion in RIP-DTA mice[1]. Pharmacokinetic Profile of GNF2133 in CD-1 Mice[1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.30mL 0.46mL 0.23mL |
11.51mL 2.30mL 1.15mL |
23.01mL 4.60mL 2.30mL |
CAS号 | 2561414-56-8 |
分子式 | C24H30N6O2 |
分子量 | 434.53 |
别名 | |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Sealed in dry,2-8°C |
溶解度 |
DMSO: 3 mg/mL(6.9 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |